Dianthus Therapeutics, Inc.
DNTH•NASDAQ•Healthcare•Biotechnology

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company’s lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOMarino Garcia
Founded2015
Employees78
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitedianthustx.com
Phone929 999 4055
Address
7 Times Square, 43rd Floor New York, New York 10036 United States

Corporate Identifiers

CIK0001690585
CUSIP252828108
ISINUS2528281080
SIC2834

Leadership Team & Key Executives

Marino Garcia M.B.A.
President, Chief Executive Officer and Director
Ryan Savitz
Chief Financial Officer and Chief Business Officer
Simrat Randhawa M.B.A., M.D.
Executive Vice President and Head of Research & Development
Edward G. Carr
Chief Accounting Officer
Judson Taylor
Senior Vice President and Head of Technical Operations
Jennifer Davis Ruff
Vice President and Head of Investor Relations and Corporate Affairs
Adam M. Veness Esq.
Senior Vice President, General Counsel and Secretary
Kristina Maximenko
Chief People Officer
Rashieda Gluck
Head of Clinical Development Operations
Scott Nogi M.B.A.
Head of Business Operations